American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis

Cox, Linda, Platts-Mills, Thomas A.E., Finegold, Ira, Schwartz, Lawrence B., Simons, F. Estelle R., Wallace, Dana V.·2007·Journal of Allergy and Clinical Immunology
DOI 10.1016/j.jaci.2007.09.032

Cited by (294)

Items 101–200 of 294

  1. Targeted Molecular Therapies in Allergy and Rhinology
    Cecelia C. Damask, Matthew W. Ryan, Thomas B. Casale, Mario Castro, Christine B. Franzese, Stella E. Lee, Joshua M. Levy, Sandra Y. Lin, Peter Lio, Anju Tripathi Peters et al. · 2020 · Otolaryngology
  2. Omalizumab: overview of pharmacology and efficacy in asthma
    Dennis K. Ledford · 2009 · Expert Opinion on Biological Therapy
  3. Targeting Mast Cells with Biologics
    Jonathan J. Lyons, Dean D. Metcalfe · 2020 · Immunology and Allergy Clinics of North America
  4. Bullous pemphigoid: A practical approach to diagnosis and management in the modern era
    Camille M. Powers, Sach Thakker, Nicholas Gulati, Jordan Talia, Danielle P. Dubin, John J. Zone, Donna Aline Culton, Zachary H. Hopkins, Jónas A. Aðalsteinsson · 2025 · Journal of the American Academy of Dermatology
  5. Hypersensitivity reactions to biologics (part II): classifications and current diagnostic and treatment approaches
    Aşkın Gülşen, Bettina Wedi, Uta Jappe · 2020 · Allergo Journal International
  6. How safe are the biologicals in treating asthma and rhinitis?
    Linda Cox · 2009 · Allergy Asthma and Clinical Immunology
  7. Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases
    Kim Jackson, Sami L. Bahna · 2020 · Expert Review of Clinical Immunology
  8. Tolerability of Omalizumab in Asthma as a Major Compliance Factor: 10-Year Follow Up
    Mona Sulaiman Al-Ahmad, Jasmina Nurkić, Ahmed Maher, Nermina A. Arifhodzic, Edin Jusufović · 2018 · Open Access Macedonian Journal of Medical Sciences
  9. Immunologic Adverse Effects of Biologics for the Treatment of Atopy
    Vivian T. Aranez, Julian L. Ambrus · 2019 · Clinical Reviews in Allergy & Immunology
  10. Value-Based, Cost-Effective Care: The Role of the Allergist-Immunologist
    Marcus S Shaker, David T. Mauger, Anne L. Fuhlbrigge · 2022 · The Journal of Allergy and Clinical Immunology In Practice
  11. Exercise and Asthma
    Shengguang Ding, Chongjun Zhong · 2020 · Advances in experimental medicine and biology
  12. Expert consensus on practical aspects in the treatment of chronic urticaria
    Andrea Bauer, Heinrich Dickel, Thilo Jakob, Andreas Kleinheinz, Undine Lippert, Martin Metz, Sibylle Schliemann, Uwe Schwichtenberg, Petra Staubach, Eva Maria Valesky et al. · 2021 · Allergo Journal International
  13. Management and Prevention of Anaphylaxis
    Anne-Marie A. Irani, Elias Akl · 2015 · F1000Research
  14. Difficult and Severe Asthma in Children
    Federica Porcaro, Nicola Ullmann, Annalisa Allegorico, Antonio Di Marco, Renato Cutrera · 2020 · Children
  15. Hypersensitivity and Immune-related Adverse Events in Biologic Therapy
    Jamie Lee Waldron, Stephen A. Schworer, Mildred Kwan · 2021 · Clinical Reviews in Allergy & Immunology
  16. Home Self-Administration of Biologics – A German Survey among Omalizumab-Treated Patients with Severe Asthma and their Treating Physicians
    Hartmut Timmermann, Claudia Mailänder · 2020 · Pneumologie
  17. The chronic rhinosinusitis practice parameter
    So Lim Kim, Matthew A. Rank, Anju Tripathi Peters · 2022 · Annals of Allergy Asthma & Immunology
  18. Anaphylaxis avoidance and management: educating patients and their caregivers
    Jarvinen, Jocelyn Celestin · 2014 · Journal of Asthma and Allergy
  19. Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma
    Maxime Luu, Marc Bardou, Philippe Bonniaud, Françoise Goirand · 2016 · Expert Opinion on Drug Metabolism & Toxicology
  20. Immunomodulatory and biologic therapies for severe refractory asthma
    Riccardo Polosa, Jaymin Bhagwanji Morjaria · 2008 · Respiratory Medicine
  21. Subcutaneous Injectable Drugs Hypersensitivity and Desensitization
    Sevim Bavbek, Min Jung Lee · 2017 · Immunology and Allergy Clinics of North America
  22. Adverse effects of biologics used to treat asthma
    Andrea N. Sitek, Sergio E. Chiarella, Thanai Pongdee · 2025 · Therapeutic Advances in Respiratory Disease
  23. Omalizumab beyond asthma
    Jorge Sánchez, Ruth Ramírez, Susana Díez, Sara Elizabeth Sus Carrizosa, Alejandro Echenique, Margarita Olivares, Ricardo Cardona · 2012 · Allergologia et Immunopathologia
  24. Parasitic (Helminthic) Infection While on Asthma Biologic Treatment: Not Everything Is What It Seems
    Laren D Tan, B. Todd Schaeffer, Abdullah Alismail · 2019 · Journal of Asthma and Allergy
  25. Recent Studies and Prospects of Biologics in Allergic Rhinitis Treatment
    Xiangning Cheng, Yue Zhou, Yuzhe Hao, Ziyi Long, Qianwen Hu, Bingyue Huo, Tianjian Xie, Shan Chen, Liuqing Zhou, Tao Zhou et al. · 2025 · International Journal of Molecular Sciences
  26. Hypersensitivity Reactions to Monoclonal Antibodies in Children
    Francesca Mori, Francesca Saretta, Annamaria Bianchi, Giuseppe Crisafulli, Silvia Maria Elena Caimmi, Lucia Liotti, Paolo Bottau, Fabrizio Franceschini, Claudia Paglialunga, Giampaolo Ricci et al. · 2020 · Medicina
  27. Review: Omalizumab in the treatment of severe asthma: efficacy and current problems
    Girolamo Pelaia, Teresa Renda, Pasquale Romeo, Maria Teresa Busceti, Rosario Maselli · 2008 · Therapeutic Advances in Respiratory Disease
  28. Anticancer Activity and Underlying Mechanism of Phytochemicals against Multiple Myeloma
    Beomku Kang, Hyunmin Park, Bonglee Kim · 2019 · International Journal of Molecular Sciences
  29. Omalizumab for chronic spontaneous urticaria in “complex” patients: data from real-life clinical practice
    Laura Vollono, Arianna Piccolo, Caterina Lanna, Maria Esposito, Mauro Bavetta, Elena Campione, Luca Bianchi, Laura Diluvio · 2019 · Drug Design Development and Therapy
  30. Biologics for atopic diseases: Indication, side effect management, and new developments
    Uta Jappe, Hendrik Beckert, Karl‐Christian Bergmann, Aşkın Gülşen, Ludger Klimek, Sandra Philipp, Julia Pickert, Michèle Myriam Rauber, Harald E. Renz, Christian Taube et al. · 2021 · Allergologie
  31. Contemporary Pharmacotherapy for Allergic Rhinitis and Chronic Rhinosinusitis
    Saied Ghadersohi, Bruce K. Tan · 2017 · Otolaryngologic Clinics of North America
  32. Are Biologics Safe in the Treatment of Atopic Dermatitis? A Review with a Focus on Immediate Hypersensitivity Reactions
    Matthew Bremmer, Samuel F. Bremmer, Shahana Baig-Lewis, Eric Lawrence Simpson · 2008 · Journal of the American Academy of Dermatology
  33. Immune response modifiers in the treatment of asthma: A PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology
    Mark C. Ballow, Cezmi A. Akdiş, Thomas B. Casale, Andrew John Wardlaw, Sally E. Wenzel, Zuhair K. Ballas, Jan O. Lötvall · 2012 · Journal of Allergy and Clinical Immunology
  34. Omalizumab en el tratamiento de la urticaria crónica inducible
    Pablo Chicharro, P. Rodríguez, DIEGO DE ARGILA · 2016 · Actas Dermo-Sifiliográficas
  35. Rapid desensitization of humanized mice with anti-human FcεRIα monoclonal antibodies
    Marat V. Khodoun, Suzanne C. Morris, Elizabeth B. Angerman, Crystal Potter, Richard F. Schuman, Mark Wunderlich, Joseph J. Maciag, Kathryn C. S. Locker, James C. Mulloy, Andrew B. Herr et al. · 2019 · Journal of Allergy and Clinical Immunology
  36. Biologics and Allergy Immunotherapy in the Treatment of Allergic Diseases
    Linda Cox · 2020 · Immunology and Allergy Clinics of North America
  37. Omalizumab in the management of patients with allergic (IgE-mediated) asthma
    Thomas Sandström · 2009 · Journal of Asthma and Allergy
  38. Immunomodulators for Asthma
    Vesselin V. Dimov, Thomas B. Casale · 2010 · Allergy Asthma and Immunology Research
  39. Biological Modulators in Eosinophilic Diseases
    Panida Sriaroon, Mark C. Ballow · 2014 · Clinical Reviews in Allergy & Immunology
  40. Off-label use of omalizumab in non-asthma conditions: new opportunities
    Jaymin Bhagwanji Morjaria, Riccardo Polosa · 2009 · Expert Review of Respiratory Medicine
  41. Monoclonal Antibodies for the Treatment of Nasal Polyps
    Thomas J. Willson, Robert M. Naclerio, Stella E. Lee · 2017 · Immunology and Allergy Clinics of North America
  42. The Prevalence of Allergic Rhinitis among Iranian Children: A Systematic Review and Meta-Analysis
    Rasoul Nasiri Kalmarzi, Pedram Ataee, Asadollah Fathollahpour, Masoud Behzadifar, Maryam Moradi, Faezeh Sharifian, Navid Kalani, Wesam Kooti · 2019 · Endocrine Metabolic & Immune Disorders - Drug Targets
  43. Biologics in dermatology: adverse effects
    Virendra Nath Sehgal, Deepika Pandhi, Ananta Khurana · 2015 · International Journal of Dermatology
  44. Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients
    Kiran Vasant Godse, Murlidhar Rajagopalan, Mukesh Girdhar, Sanjiv Kandhari, Bela Shah, PrashantN Chhajed, Sushil T Tahiliani, DS Krupa Shankar, Vijay Kumar Somani, Vijay P. Zawar · 2016 · Indian Dermatology Online Journal
  45. Biologics in asthma: difficulties and drawbacks
    Jean Bousquet, R. Chiron, Marc J.C. Humbert · 2008 · Expert Opinion on Biological Therapy
  46. Therapeutical Targets in Allergic Inflammation
    Lorenzo Salvati, Francesco Liotta, Francesco Annunziato, Lorenzo Cosmi · 2022 · Biomedicines
  47. Omalizumab in the Treatment of Chronic Urticaria
    Laura Soto Francés, Maria del Carmen Leiva-Salinas, J.F. Silvestre · 2014 · Actas Dermo-Sifiliográficas
  48. Immunomodulators in asthma therapy
    Vesselin V. Dimov, Jeffrey R. Stokes, Thomas B. Casale · 2009 · Current Allergy and Asthma Reports
  49. Pharmacotherapy of severe asthma
    Rafael Firszt, Monica Kraft · 2010 · Current Opinion in Pharmacology
  50. Pharmakoprophylaxe und Begleitmedikation bei spezifischer Immuntherapie
    Bettina Wedi, Franziska Ruëff · 2011 · Der Hautarzt
  51. Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness?
    Ragıp Ertaş, Kemal Özyurt, Sinem Yıldız, Yılmaz Ulaş, Abdullah Turasan, Atıl Avcı · 2016 · PubMed
  52. The use of biologics in children with allergic rhinitis and chronic rhinosinusitis: Current updates
    Tan Shinee, Budi Sutikno, Baharudin Abdullah · 2019 · Pediatric Investigation
  53. Biological therapy-associated adverse reactions in asthma: analysis of reporting to the Portuguese pharmacovigilance system
    José Luís Carneiro Sousa, Luís Taborda‐Barata, Cristina Sofia de Jesus Monteiro · 2019 · Expert Opinion on Drug Safety
  54. Anti-Immunoglobulin E Therapy
    Manav Segal, Jeffrey R. Stokes, Thomas B. Casale · 2008 · World Allergy Organization Journal
  55. Omalizumab en el tratamiento de la urticaria crónica
    Laura Soto Francés, Maria del Carmen Leiva-Salinas, J.F. Silvestre · 2013 · Actas Dermo-Sifiliográficas
  56. Multicentre experience of home omalizumab treatment for chronic spontaneous urticaria
    Sarah Denman, Tariq El-shanaway, Emily M. Carne, Lisa Devlin, Sinisa Savic · 2019 · European Journal of Hospital Pharmacy
  57. Use of biologicals as immunotherapy in asthma and related diseases
    Brandie Walker, Richard Leigh · 2008 · Expert Review of Clinical Immunology
  58. Phenotyping severe asthma: a rationale for biologic therapy
    Alessandro Vatrella, Angelantonio Maglio, Simona Pellegrino, Corrado Pelaia, Cristiana Stellato, Girolamo Pelaia, Carolina Vitale · 2020 · Expert Review of Precision Medicine and Drug Development
  59. A risk of serious anaphylatic reactions to asthma biologics: a pharmacovigilance study based on a global real-world database
    Sunny Park, Yeju Kim, Geon Ho Lee, Soo An Choi · 2023 · Scientific Reports
  60. Omalizumab‐induced triphasic anaphylaxis in a patient with chronic spontaneous urticaria
    Müzeyyen Gönül, A. Özenergün Bittacı, C. Ergin · 2015 · Journal of the European Academy of Dermatology and Venereology
  61. Allergic and Pseudoallergic Drug Reactions
    Lynne M. Sylvia · 2014
  62. Anaphylaxis to three humanized antibodies for severe asthma: a case study
    Koichi Jingo, Norihiro Harada, Toshihiko Nishioki, Masahiro Torasawa, Tomoko Yamada, Tetsuhiko Asao, Haruhi Takagi, Tomohito Takeshige, Jun Ito, Kazuhisa Takahashi · 2020 · Allergy Asthma and Clinical Immunology
  63. Omalizumab: Not Only For Asthma
    Moshe Ben‐Shoshan · 2008 · Recent Patents on Inflammation & Allergy Drug Discovery
  64. A Review of Adverse Reactions to Biologics Used in Allergy-Immunology Practice
    Timothy G. Chow, John Oppenheimer, Shyam R. Joshi · 2022 · The Journal of Allergy and Clinical Immunology In Practice
  65. A comprehensive review on natural products caused allergy and its mechanism
    Sankhadip Bose, Partha Pratim Das, Sabyasachi Banerjee, Pranabesh Chakraborty · 2023 · Journal of Herbal Medicine
  66. Future Forms of Immunotherapy and Immunomodulators in Allergic Disease
    Tran‐Hoai T. Nguyen, Jeffrey R. Stokes, Thomas B. Casale · 2011 · Immunology and Allergy Clinics of North America
  67. Self-Administered Mepolizumab in the Management of Severe Asthma: Usability and Patient Acceptance
    Reika Miyokawa, Celeste Kivler, Samuel Louie, Dorottya Gódor, Laren D Tan, Nicholas J. Kenyon · 2020 · Patient Preference and Adherence
  68. Pathophysiology and Organ Damage in Anaphylaxis
    Stephen F. Kemp, Richard F. Lockey · 2010 · Humana Press eBooks
  69. Anti-IgE in the treatment of allergic disorders in pediatrics
    Ari J. Fried, Hans C. Oettgen · 2010 · Current Opinion in Pediatrics
  70. Current practices among allergists on writing self-injectable epinephrine prescriptions for immunotherapy patients
    Payel Gupta, Prianka K. Gerrish, Bernard A. Silverman, Arlene T. Schneider · 2011 · Journal of Allergy and Clinical Immunology
  71. Asthma that is unresponsive to usual care
    Kenneth R. Chapman, Andrew McIvor · 2009 · Canadian Medical Association Journal
  72. Biologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on hypersensitivity reactions
    Uta Jappe, Karl‐Christian Bergmann, Folke Brinkmann, Valentina Faihs, Aşkın Gülşen, Ludger Klimek, Harald Renz, Sebastian Seurig, Christian Taube, Stephan Traidl et al. · 2024 · Allergologie select
  73. Omalizumab in the Treatment of Chronic Inducible Urticaria
    Pablo Chicharro, P. Rodríguez, DIEGO DE ARGILA · 2017 · Actas Dermo-Sifiliográficas
  74. Biologics as treatment options for anaphylaxis
    Arianna Cafarotti, Alessandro Giovanni Fiocchi, Stefania Arasi · 2021 · Current Opinion in Allergy and Clinical Immunology
  75. Current and Emerging Biologic Therapies for Severe Asthma
    Mario Cazzola, Maria Gabriella Matera, Josuel Ora, Luigino Calzetta, Paola Rogliani · 2026 · Drugs
  76. Role of clinical biomarkers in predicting the effectiveness of omalizumab
    Qing Zhang, Chunxiao Li, Jingxuan Wan, Mengyuan Zhang, Ying Nong, Jiangtao Lin · 2023 · Therapeutic Advances in Respiratory Disease
  77. A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database
    Yongfu Song, Zhuang Wang, Na Wang, Xiaofei Xie, Tieshi Zhu, Yongji Wang · 2025 · Scientific Reports
  78. A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema
    David Michael Lang · 2014 · Annals of Allergy Asthma & Immunology
  79. Anaphylaxis to Drugs, Biological Agents, and Vaccines
    Ruchi Shah, Margaret M. Kuder, David Michael Lang · 2021 · Immunology and Allergy Clinics of North America
  80. Considerations for the Use of Biologics in Chronic Rhinosinusitis With Nasal Polyps
    Hannah G. Luk, Tyler A. Janz, Farrah N. Siddiqui, Scott A. Hardison · 2025 · Ear Nose & Throat Journal
  81. Immunogenicity of Biological Agents: Basic Knowledge and Clinical Implications
    Andrea Matucci, Francesca Nencini, Enrico Maggi, Alessandra Vultaggio · 2014 · Florence Research (University of Florence)
  82. Options of immunotherapeutic treatments for children with asthma
    Federica Porcaro, Renato Cutrera, Giovanni Battista Pajno · 2019 · Expert Review of Respiratory Medicine
  83. The place of Omalizumab in the treatment of allergic diseases
    Oksana Mikhaylovna Kurbacheva, M A Galitskaya · 2019 · Meditsinskiy sovet = Medical Council
  84. Benefits and Risks of Long-Term Asthma Management in Children: Where Are We Heading?
    Hengameh Raissy, H. William Kelly · 2016 · Drug Safety
  85. Omalizumab for asthma: pharmacology and clinical profile
    Leandro Genehr Fritscher, Kenneth R. Chapman · 2009 · Expert Review of Respiratory Medicine
  86. Omalizumab in “non–IgE-mediated” diseases
    R. Sharon Chinthrajah, Stephen Joseph Galli · 2020 · Journal of Allergy and Clinical Immunology
  87. Implementing Food Oral Immunotherapy Into Clinical Practice: Quality and Safety Perspectives From a US Academic Center
    Andrew W. Winslow, Christa Mills, Justin T. Schwartz, Amal Assa’ad · 2024 · The Journal of Allergy and Clinical Immunology In Practice
  88. Traditional Therapies for Severe Asthma
    Eileen Wang, Flavia Cecilia Lega Hoyte · 2016 · Immunology and Allergy Clinics of North America
  89. Recommandations de la Société Française d’Allergologie. Indications des actes allergologiques en Hôpital de Jour
    Cindy Barnig, A. Baron-Thurotte, Annick M. Barbaud, É. Beaudouin, Frederic de BLAY, Philippe Bonniaud, Pascal M. Demoly, A. Deschildre, Alain P. Didier, M. Drouet et al. · 2017 · Revue française d'allergologie
  90. Biologics for Asthma and Risk of Infection
    João Pedro Lopes, Mauli Desai · 2019 · Immunology and Allergy Clinics of North America
  91. [Retrospective analysis of omalizumab in patients with severe allergic asthma].
    Núria Padullés Zamora, Dolors Comas Sugrañes, Nadia Mendez Cabaleiro, A. Figueras-Suriol, Ramón José Jódar Masanés · 2013 · PubMed
  92. Investigational drugs for allergic rhinitis
    Giovanni Passalacqua, Enrico Compalati, Giorgio Walter Canonica · 2009 · Expert Opinion on Investigational Drugs
  93. Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases
    Jean Bousquet, Ulrich Wahn, Eli O. Meltzer, H. Fox, Simon Hedgecock, K. Thomas, Angel FowlerTaylor · 2008 · European Respiratory Review
  94. Asthma
    Njira Lucia Lugogo, Loretta G. Que, Daniel L Gilstrap, Monica Kraft · 2015 · Elsevier eBooks
  95. Unerwünschte Arzneimittelreaktionen an der Haut
    Kathrin Scherer, Andreas J. Bircher · 2008 · Der Internist
  96. Challenges in the Management of Severe Asthma: Role of Current and Future Therapies
    Ron Oliveinstein, Hamdan Al Jahdali, Nouf Alkhamis, Rabih Halwani, Saleh Al‐Muhsen, Qutayba A. Hamid · 2011 · Current Pharmaceutical Design
  97. Might Selective B-Cell Depletion have a Place in Targeted Allergy Therapy?
    Michael A. Firer · 2014 · Journal of Hematology Research
  98. Anaphylactic risks associated with immunobiological agents in asthma therapy
    José Antônio Baddini Martínez, Fernando Sergio Leitão Filho, Lilian Ballini Caetano · 2023 · Revista da Associação Médica Brasileira
  99. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience
    Ayda Acar, Bengü Gerçeker Türk, İlgen Ertam, Can Ceylan, Günseli Öztürk, İdil Ünal · 2020 · Cutaneous and Ocular Toxicology
  100. Omalizumab treatment for chronic spontaneous urticaria: data from Turkey
    Rabia Öztaş Kara, Bahar Sevimli Dikicier, Mahizer Yaldız, Busra Koku, Nur Cihan Coşansu, Berna Solak · 2022 · Advances in Dermatology and Allergology